Patient-reported toxicity symptoms during tyrosine kinase inhibitor treatment in chronic myeloid leukemia: a systematic review and meta-analysis
Supportive Care in Cancer · 2025-05 · 33 (5)
DOI: 10.1007/s00520-025-09451-4 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Supportive Care in Cancer, online erschienen am 03.05.2025. Verfasst von Yolba Smit und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, Radboud university medical center, Route 476, P.O. Box 9101, 6500 HB, Nijmegen, The Netherlands. yolba.smit@radboudumc.nl. Hauptthemen laut MEDLINE: Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Protein Kinase Inhibitors, Antineoplastic Agents. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 73 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Purpose
One in five chronic myeloid leukemia (CML) patients experiences such intolerability that they switch tyrosine kinase inhibitor (TKI) treatment within 3 years. Information on tolerability is needed to guide shared decision-making. However, an overview of symptoms patients experience per TKI is lacking, and physician-graded toxicity underestimates patients’ experiences.
Methods
We systematically searched PubMed and Embase from inception to February 2025 and conducted a meta-analysis on the prevalence of patient-reported symptoms in CML per TKI. This study follows the Preferred Reporting Items for Systematic Reviews (PRISMA) guideline for systematic reviews.
Results
We included 11 studies with 2987 patients, reporting on 47 different symptoms of any severity. The low-grade patient-reported symptom burden was high. No data were available on asciminib and ponatinib, and minimal data were available for bosutinib. In indirect, unadjusted comparisons, 13 out of 47 symptoms (of any severity) showed significant differences in prevalence between common TKI types.
Conclusion
Our findings provide essential information to guide treatment decisions in cases of intolerability. However, there is a clear need for further research with standardized instruments, especially in second and third generation TKI types, including direct comparisons and comparisons adjusted for covariates.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Hematology, Radboud university medical center, Route 476, P.O. Box 9101, 6500 HB, Nijmegen, The Netherlands. yolba.smit@radboudumc.nl.
- Department of Hematology, Radboud university medical center, Route 476, P.O. Box 9101, 6500 HB, Nijmegen, The Netherlands.
- Department of Internal Medicine, Reinier de Graaf Hospital, Delft, The Netherlands.
- Department of Pharmacy, Radboud university medical center, Nijmegen, The Netherlands.
- Department of IQ Health, Radboud university medical center, Nijmegen, The Netherlands.
Zitieren
APA
Smit, Y., Scheuter, P., Lange, M. P. M., Janssen, J. J. W. M., Posthuma, E. F. M., Bekker, C. L., Hermens, R. P. M. G., & Blijlevens, N. M. A. (2025). Patient-reported toxicity symptoms during tyrosine kinase inhibitor treatment in chronic myeloid leukemia: a systematic review and meta-analysis. Supportive Care in Cancer, 33(5). https://doi.org/10.1007/s00520-025-09451-4
Vancouver
Smit Y, Scheuter P, Lange MPM, Janssen JJWM, Posthuma EFM, Bekker CL, et al. Patient-reported toxicity symptoms during tyrosine kinase inhibitor treatment in chronic myeloid leukemia: a systematic review and meta-analysis. Supportive Care in Cancer. 2025;33(5). doi:10.1007/s00520-025-09451-4
BibTeX
@article{Smit2025,
author = {Smit, Yolba and Scheuter, Pien and Lange, Myrthe P M and Janssen, Jeroen J W M and Posthuma, Eduardus F M and Bekker, Charlotte L and Hermens, Rosella P M G and Blijlevens, Nicole M A},
title = {Patient-reported toxicity symptoms during tyrosine kinase inhibitor treatment in chronic myeloid leukemia: a systematic review and meta-analysis},
journal = {Supportive Care in Cancer},
year = {2025},
volume = {33},
number = {5},
doi = {10.1007/s00520-025-09451-4}
}
EUVIMED